Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1979 Apr;17(4):171-5.

Pharmacokinetics of Amikacin (BB-K8) in patients with normal or impaired renal function

  • PMID: 447438

Pharmacokinetics of Amikacin (BB-K8) in patients with normal or impaired renal function

J M Lanao et al. Int J Clin Pharmacol Biopharm. 1979 Apr.

Abstract

The pharmacokinetics of Amikacin (BB-K8) were determined after a single i.v. injection of 7.8 mg of the antibiotic/kg of body weight. It was administered to 10 patients with normal renal function and 19 patients with varying degrees of renal impairment. The elimination of Amikacin from plasma was seen to follow the course of an open two-compartment model system. From patients with normal renal function, values for the following pharmacokinetic parameters were obtained: alpha = 4.219 hr-1; beta = 0.292 hr-1; K12 = 2.218 hr-1; K21 = 0.859 hr-1; K13 = 1.432 hr-1; Vc = 3.125 1; Vp = 8.068 1 and Vdss = 11.193 1. As the relationship K12/K21 is greater than 1, it may be seen that there is a tendency for the antibiotic to accumulate in the peripheric compartment. Impaired renal function significantly diminishes the values recorded for alpha, beta, K12, K21, K13. Distribution volumes are significantly increased in patients with renal impairment. A linear relationship between the K13 of Amikacin and creatinine clearance is demonstrated. Adjustment of Amikacin dosage, according to the individual degree of renal impairment, may be obtained by spacing out the injections.

PubMed Disclaimer

Similar articles

Cited by

  • Renal elimination of amikacin and the aging process.
    Ducher M, Maire P, Cerutti C, Bourhis Y, Foltz F, Sorensen P, Jelliffe R, Fauvel JP. Ducher M, et al. Clin Pharmacokinet. 2001;40(12):947-53. doi: 10.2165/00003088-200140120-00004. Clin Pharmacokinet. 2001. PMID: 11735610

LinkOut - more resources